Vanda Pharmaceuticals Inc.

Paolo Baroldi

Mihael Hristos Polymeropoulos

Curt Douglas Wolfgang

Marlene Michelle Dressman

One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering the tasimelteon without food, no food at least &#xbd; hour prior to administration, no food at least 1 hour prior to administration, no food at least 1&#xbd; hours prior to administration, no food at least 2 hours prior to administration, no food at least 2&#xbd; hours prior to administration, or no food at least 3 hours prior to administration. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg/d. Tasimelteon may be administered where, for example, the patient is being treated for a circadian rhythm disorder or for a sleep disorder, including, for example, Non-24 Disorder.

Method of treatment

Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.

Method and composition for treating an alpha adrenoceptor-mediated condition

A method and composition for treating serotonin receptor-mediated conditions.

Growing community of inventors

Potomac, MD, United States of America

Paolo Baroldi